PRODUCT LITERATURE

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

---

The platelet glycoprotein IIb/IIIa inhibitors, although effective in reducing ischaemic complications of percutaneous coronary intervention, are used in few coronary stent implantation procedures. ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy) is a randomised, placebo-controlled trial to assess whether a novel, double-bolus dose of eptifibatide could improve outcomes of patients undergoing coronary stenting

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

LITERATURE

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Ebatid

Specific Detail Info

Lancet 2000; 356: 2037–44

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment